Single cell suspension was obtained as previously described (34 (link)). The cells were stained with antibodies, purchased from either BioLegend [anti-CD3e (145-2C11, RRID: AB_312660), anti-CD8𝛼 (53-6.7, RRID: AB_2888883), anti-CD11b (M1/70, RRID: AB_312791), anti-CD25 (PC61.5, RRID: AB_312847), anti-CD29 (HMβ1-1, RRID: AB_312885), anti-CD31 (390, RRID: AB_10613644), anti-CD45 (30-F11, RRID: AB_2563598), anti-CD140a (PDGFRα, RRID: AB_1953268, APA5), anti-CD324 (EpCAM, G8.8, RRID: AB_1134172), anti-VEGFR3 (AFL4, AB_10680790), and anti-PDPN (8.1.1, RRID: AB_2629802)] or from Thermo Fisher Scientific [anti-CD4 (RM4-5, RRID: AB_464902), anti-CD69 (H1.2F3, RRID: AB_1210795), anti-FoxP3 (FJK-16s, RRID:AB_467575), and anti-NK1.1 (PK136, RRID: AB_2536075)] or from Abcam [anti-αSMA (EPR5368, RRID: AB_11129103)]. Cells were also stained with Fixable Viability Dye (Thermo Fisher Scientific) and dead cells were gated out from the analysis. Cell types were determined as following; lymphatic cells: CD45+/CD3+, CD8 T+ cells: CD45+/CD3+/CD8+, Tregs: CD45+/CD3+/CD4+/FoxP3+, cancer cells (MOC1): CD45/ CD31/EpCAM+/CD140a/VEGFR3, cancer cells (MC38-luc): CD45/CD31/CD29+/αSMA, CAFs (MOC1): CD45/CD31/EpCAM/CD140a+/VEGFR3, CAFs (MC38-luc): CD45/CD31/αSMA+, vascular endothelial cells: CD45/CD31+/EpCAM/CD140a/VEGFR3, lymphatic endothelial cells: CD45/CD31/EpCAM/CD140a/VEGFR3+.